Patents by Inventor Guoqiang Wang

Guoqiang Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12281140
    Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Grant
    Filed: May 4, 2023
    Date of Patent: April 22, 2025
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Yat Sun Or, Ruichao Shen, Jiang Long, Peng Dai, Xuechao Xing, Jing He
  • Patent number: 12223068
    Abstract: A secure computing control method, a data packet processing method and device, and a system thereof are disclosed. The secure computing method may include: receiving a first data packet message for secure computing from a processor, the first data packet message including data packet information and secure computing configuration information corresponding to the data packet information; acquiring corresponding first data packet data from a memory according to the data packet information of the first data packet message; selecting a corresponding security algorithm according to the secure computing configuration information corresponding to the first data packet message; performing secure computing on the first data packet data by the selected security algorithm to generate secure computed second data packet data and a second data packet message corresponding to the second data packet data; transmitting the second data packet data to the memory; and transmitting the second data packet message to the processor.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: February 11, 2025
    Assignee: ZTE CORPORATION
    Inventors: Jie Liu, Haibo Wang, Guoqiang Wang, Yubin Xu
  • Publication number: 20250000588
    Abstract: A system (100) and a method for puncture path planning are provided. The system (100) comprises: at least one storage medium including a set of instructions; and one or more processors (210) communicating with the at least one storage medium. When executing the instructions, the one or more processors (210) are used to: determine a target point (410) based on a target image; determine one or more candidate paths (420) based on the target point and at least two constraints, wherein in the process of determining the one or more candidate paths, a path planning condition is adaptively adjusted based on a first preset condition; and determine a target path (430) based on the one or more candidate paths.
    Type: Application
    Filed: September 16, 2024
    Publication date: January 2, 2025
    Applicant: WUHAN UNITED IMAGING SURGICAL CO., LTD.
    Inventors: Guoqiang WANG, Mingzhe LIAO, Ke WANG, Wei FANG, Jing ZHANG, Tian ZHANG
  • Patent number: 12183748
    Abstract: An array substrate including a display area having a plurality of subpixels is provided. The plurality of subpixels includes a plurality of first subpixels in a display-bonding sub-area and a plurality of second subpixels in a regular display sub-area. The array substrate includes a plurality of thin film transistors on a first side of the base substrate and respectively in the plurality of subpixels. A respective one of the plurality of first subpixels includes a bonding pad on a second side of a base substrate; a lead line electrically connecting a respective one of a plurality of thin film transistors to the bonding pad; and a via extending through the base substrate. The lead line is unexposed in the array substrate. The lead line extends from the first side to the second side of the base substrate through the via, to connect to the bonding pad.
    Type: Grant
    Filed: November 23, 2023
    Date of Patent: December 31, 2024
    Assignee: BOE Technology Group Co., Ltd.
    Inventors: Ke Wang, Muxin Di, Zhiwei Liang, Guoqiang Wang, Renquan Gu, Xiaoxin Song, Xiaoyan Zhu, Yingwei Liu, Zhanfeng Cao
  • Publication number: 20240376079
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Application
    Filed: May 10, 2024
    Publication date: November 14, 2024
    Inventors: Guoqiang WANG, Ruichao SHEN, Jiang LONG, Jun MA, Xuechao XING, Yong HE, Brett GRANGER, Jing HE, Bin WANG, Yat Sun OR
  • Publication number: 20240327452
    Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Application
    Filed: March 5, 2024
    Publication date: October 3, 2024
    Inventors: Guoqiang WANG, Yat Sun OR, Ruichao SHEN, Xuechao XING, Jiang LONG, Peng DAI, Brett GRANGER, Jing HE
  • Patent number: 12062744
    Abstract: The present disclosure relates to a display substrate, a display device, and a method for manufacturing a display substrate. The display substrate includes a base substrate having a first side and a second side opposite to the first side, a via provided in the base substrate, a thin film transistor provided on the first side of the base substrate, a first conductive structure provided on the first side of the base substrate, wherein a first sub-portion of the first conductive structure is located in the via, and wherein a material of the first conductive structure is the same as a material of a source/drain electrode of the thin film transistor.
    Type: Grant
    Filed: October 12, 2019
    Date of Patent: August 13, 2024
    Assignee: BOE TECHNOLOGY GROUP CO., LTD.
    Inventors: Muxin Di, Ke Wang, Guoqiang Wang, Zhiwei Liang, Renquan Gu, Yingwei Liu, Qi Yao, Zhanfeng Cao
  • Publication number: 20240228464
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: October 26, 2023
    Publication date: July 11, 2024
    Inventors: Guoqiang Wang, Ruichao Shen, Brett Granger, Jing He, Xuechao Xing, Yong He, Jiang Long, Jun Ma, Bin Wang, Yat Sun Or
  • Publication number: 20240212870
    Abstract: A coating for protecting a Zirconium alloy based layer of a nuclear fuel rod cladding is provided. The coating comprises a primary layer. A microstructure of the primary layer is comprised of a number of grains and is randomized. The primary layer is configured with a density of about 94.5% or greater. A cladding for a nuclear fuel rod and a method for producing a cladding for a nuclear fuel rod are also provided.
    Type: Application
    Filed: December 21, 2022
    Publication date: June 27, 2024
    Applicant: Westinghouse Electric Company LLC
    Inventors: Edward J. LAHODA, Elwyn ROBERTS, Benjamin R. MAIER, Allan Wayne JAWORSKI, JR., Arash PARSI, Guoqiang WANG, William A. BYERS, Jorie WALTERS, Chona P. VALLENCOUR, John Leo LYONS, Luke CZERNIAK, Roy J. MATWAY, Gregory E. ROBERTS, Kathryn E. METZGER, Jonathan WRIGHT, Luke C. OLSON, Denise ADORNO-LOPES
  • Patent number: 12018017
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Grant
    Filed: December 2, 2022
    Date of Patent: June 25, 2024
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Ruichao Shen, Jiang Long, Jun Ma, Xuechao Xing, Yong He, Brett Granger, Jing He, Bin Wang, Yat Sun Or
  • Patent number: 12006291
    Abstract: The present invention relates to processes for preparing a Compound (1): or a pharmaceutically acceptable salt or solvate thereof. Compound (1) is useful as in many pharmaceutical agents, especially is useful as key intermediate in the synthesis of certain SARS-CoV-2 3CLpro inhibitors.
    Type: Grant
    Filed: January 10, 2023
    Date of Patent: June 11, 2024
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Kaicheng Zhu, Tao Wang, Jiajun Zhang, Hui Cao, Ruichao Shen, Guoqiang Wang, George G. Wu, Yat Sun Or
  • Publication number: 20240173714
    Abstract: A detection result reading device is provided. The detection result reading device includes a reading device body. The reading device body is provided with a cavity at least capable of accommodating a detection part of a reagent card. A side wall of the cavity is provided with a detection result acquisition device, and the detection result acquisition device is arranged opposite to the detection part of the reagent card. The reading device body is provided with a lifting device for lifting the detection part of the reagent card towards a side of the cavity close to the detection result acquisition device.
    Type: Application
    Filed: September 28, 2021
    Publication date: May 30, 2024
    Applicant: JIANGSU BIOPERFECTUS TECHNOLOGIES CO., LTD.
    Inventors: Chunchun HU, Renyuan CHEN, Haidong SHEN, Fancheng WEI, Xin WANG, Wei JIN, Zhonghua LIU, Guoqiang WANG
  • Publication number: 20240149265
    Abstract: An auxiliary test paper detection device includes a reagent cap and a test paper cassette. The reagent cap contains a detection reagent, a sealing member is arranged at an opening of the reagent cap. The sealing member can be opened or removed under action of external force. Test paper is arranged in the test paper cassette, a sample absorption section of the test paper is exposed, an observation window is formed in the test paper cassette. A result display area of the test paper corresponds to the observation window. A connecting structure for connecting the test paper cassette and the reagent cap is provided, and when the test paper cassette and the reagent cap are connected through the connecting structure, a closed space is formed in an inner cavity of the reagent cap. The sample absorption section of the test paper extends into the inner cavity of the reagent cap.
    Type: Application
    Filed: September 26, 2021
    Publication date: May 9, 2024
    Applicant: JIANGSU BIOPERFECTUS TECHNOLOGIES CO., LTD.
    Inventors: Qianqian Shang, Qianqian JIA, Xinyi JIANG, Linping TAN, Xin WANG, Fancheng WEI, Renyuan CHEN, Wei JIN, Zhonghua LIU, Guoqiang WANG
  • Patent number: 11976084
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 22, 2021
    Date of Patent: May 7, 2024
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Ruichao Shen, Jun Ma, Yong He, Xuechao Xing, Hui Cao, Xuri Gao, Xiaowen Peng, Joseph D. Panarese, Yat Sun Or
  • Publication number: 20240140984
    Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Application
    Filed: May 4, 2023
    Publication date: May 2, 2024
    Inventors: Guoqiang WANG, Yat Sun OR, Ruichao SHEN, Jiang LONG, Peng DAI, Xuechao XING, Jing HE
  • Publication number: 20240132476
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: October 25, 2023
    Publication date: April 25, 2024
    Inventors: Guoqiang Wang, Ruichao Shen, Brett Granger, Jing He, Xuechao Xing, Yong He, Jiang Long, Jun Ma, Bin Wang, Yat Sun Or
  • Patent number: 11958879
    Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: April 16, 2024
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Yat Sun Or, Ruichao Shen, Xuechao Xing, Jiang Long, Peng Dai, Brett Granger, Jing He
  • Publication number: 20240116950
    Abstract: Provided are small molecule inhibitors of the KRAS(G12D) mutant oncoprotein having the structural formula: and pharmaceutically acceptable salts and compositions thereof, which are useful for treating cancers and related conditions.
    Type: Application
    Filed: September 8, 2023
    Publication date: April 11, 2024
    Inventors: Weiwen Ying, Chenghao Ying, Kevin P. Foley, Zhiyong Wang, Wei Yin, Liang Ma, Guoqiang Wang, Jinhua Li, Yaya Wang, Yan Dai, Thomas Prince
  • Patent number: 11945824
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: October 18, 2021
    Date of Patent: April 2, 2024
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yat Sun Or, Yong He, Kevin McGrath, Ruichao Shen, Adam Szymaniak, Xuechao Xing, In Jong Kim, Guoqiang Wang
  • Publication number: 20240088170
    Abstract: An array substrate including a display area having a plurality of subpixels is provided. The plurality of subpixels includes a plurality of first subpixels in a display-bonding sub-area and a plurality of second subpixels in a regular display sub-area. The array substrate includes a plurality of thin film transistors on a first side of the base substrate and respectively in the plurality of subpixels. A respective one of the plurality of first subpixels includes a bonding pad on a second side of a base substrate; a lead line electrically connecting a respective one of a plurality of thin film transistors to the bonding pad; and a via extending through the base substrate. The lead line is unexposed in the array substrate. The lead line extends from the first side to the second side of the base substrate through the via, to connect to the bonding pad.
    Type: Application
    Filed: November 23, 2023
    Publication date: March 14, 2024
    Applicant: BOE Technology Group Co., Ltd.
    Inventors: Ke Wang, Muxin Di, Zhiwei Liang, Guoqiang Wang, Renquan Gu, Xiaoxin Song, Xiaoyan Zhu, Yingwei Liu, Zhanfeng Cao